Trial Endpoints for Candidemia and Invasive Candidiasis: Consensus Recommendations by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology
Year: 2026
Type: article
Abstract: Invasive candidiasis (IC) remains the most common invasive mycosis world-wide, responsible for a wide range of infections that can range from superficial mucosal infections to life-threatening systemic diseases. Clinical trials of antifungal agents for IC are pivotal to its management. Therapeutic responses in these trials are currently based on consensus criteria initially presented by the Mycoses Study Group (MSG) and the European Organization for Research and the Treatment of Cancer (EORTC) in 2008. These 2008 definitions originally described by Segal et al are still employed by both investigators and regulatory agencies when evaluating antifungal drug efficacy and patient outcomes. However, advances in clinical mycology, the change in epidemiology of Candida infections due to the increase in non-albicans Candida species, and the increase in newer antifungal agents currently under development require a revision of these criteria to ensure appropriate and standardized adjudication of patient outcomes and to accurately capture responses to newer therapeutic regimens and modern interventions. Therefore, the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) have decided to revise the criteria to be used for future studies.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciag583
Institutions: Augusta University, Augusta University Health, Westmead Hospital, NSW Health Pathology, Johns Hopkins University, Johns Hopkins Medicine, Duke University, Duke Medical Center, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Investigación Sanitaria Gregorio Marañón, Medical University of Graz, Municipality of Medellín, Corporación para Investigaciones Biológicas, University of Maryland, Baltimore, University of Münster, University Hospital Münster, University of Delhi, University of California Davis Medical Center, University of California, Davis, University of California San Diego, Hacettepe University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,763
OpenAlex ID: W7235183116
